BRIEF—Novo Nordisk invests 650 million kroner to expand production facilities

Danish diabetes care giant Novo Nordisk today announced plans to invest 650 million Danish kroner ($98.5 million) in upgrading and expanding facilities at its production site in Kalundborg, Denmark.

The facilities in question are currently manufacturing a range of products for diabetes treatment and will be rebuilt to allow for future production of the next generation of products. The projects are expected to be completed in 2020.

"The investments in production facilities highlight Novo Nordisk's ambition to continue strengthening its presence in Denmark and Kalundborg. Today, Novo Nordisk manufactures around half of the world's insulin in Kalundborg and we have had a presence in Kalundborg for 50 years. Since the turn of the millennium alone, Novo Nordisk has invested more than 15 billion kroner in Kalundborg, which is a cornerstone of the company's global production network," says Michael Hallgren, senior vice presiden for Novo Nordisk production in Kalundborg.

Novo Nordisk's production site in Kalundborg also houses production facilities for Novozymes.